Review: taking Ddavp and Abilify together


Summary

Drug interactions are reported among people who take Ddavp and Abilify together. This review analyzes the effectiveness and drug interactions between Ddavp and Abilify. It is created by eHealthMe based on reports of 36 people who take the same drugs from FDA and social media, and is updated regularly.

You are not alone

Join a support group for people who take Ddavp and Abilify >>>

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA and social media since 1977. Our tools are free and anonymous. 86 million people have used us. 300+ peer-reviewed medical journals have referenced our original studies. Start now >>>


Ddavp

Ddavp has active ingredients of desmopressin acetate. It is often used in diabetes insipidus. (latest outcomes from Ddavp 1,411 users)

Abilify

Abilify has active ingredients of aripiprazole. It is often used in bipolar disorder. (latest outcomes from Abilify 29,792 users)

On Jul, 23, 2016

36 people who take Ddavp, Abilify are studied.


Number of reports submitted per year:

Ddavp and Abilify drug interactions.

Drug effectiveness over time:

Ddavp:
  • < 1 month: 0.0% - (0 of 1 people)
  • 1 - 6 months: 0.0% - (0 of 2 people)
  • 6 - 12 months: 0.0% - (0 of 1 people)
  • 1 - 2 years: 100.0% - (1 of 1 people)
  • 2 - 5 years: 0.0% - (0 of 0 people)
  • 5 - 10 years: 0.0% - (0 of 0 people)
  • 10+ years: 0.0% - (0 of 0 people)
  • not specified: 0.0% - (0 of 0 people)
Abilify:
  • < 1 month: 0.0% - (0 of 0 people)
  • 1 - 6 months: 50.0% - (1 of 2 people)
  • 6 - 12 months: 0.0% - (0 of 1 people)
  • 1 - 2 years: 0.0% - (0 of 0 people)
  • 2 - 5 years: 0.0% - (0 of 1 people)
  • 5 - 10 years: 0.0% - (0 of 0 people)
  • 10+ years: 0.0% - (0 of 0 people)
  • not specified: 0.0% - (0 of 0 people)

Drug effectiveness by gender:

Ddavp:
  • female: 100.0% - (1 of 1 people)
  • male: 0.0% - (0 of 4 people)
Abilify:
  • female: 0.0% - (0 of 0 people)
  • male: 25.0% - (1 of 4 people)

Drug effectiveness by age:

Ddavp:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 100.0% - (1 of 1 people)
  • 10-19: 0.0% - (0 of 4 people)
  • 20-29: 0.0% - (0 of 0 people)
  • 30-39: 0.0% - (0 of 0 people)
  • 40-49: 0.0% - (0 of 0 people)
  • 50-59: 0.0% - (0 of 0 people)
  • 60+: 0.0% - (0 of 0 people)
Abilify:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 25.0% - (1 of 4 people)
  • 20-29: 0.0% - (0 of 0 people)
  • 30-39: 0.0% - (0 of 0 people)
  • 40-49: 0.0% - (0 of 0 people)
  • 50-59: 0.0% - (0 of 0 people)
  • 60+: 0.0% - (0 of 0 people)

Most common drug interactions over time *:

< 1 month:
  • blood glucose increased
  • diabetes mellitus insulin-dependent
  • drug ineffective
  • nausea
  • urine ketone body present
1 - 6 months:
  • faecal incontinence
  • sedation
  • urinary incontinence
  • appetite increased
  • hallucinations
  • parkinsonism
  • tardive dyskinesia
  • thirst
  • weight gain
6 - 12 months:
  • weight gain
  • hallucinations
1 - 2 years:
  • blood glucose increased
  • diabetes mellitus insulin-dependent
  • drug ineffective
  • dyskinesia
  • nausea
  • psychomotor hyperactivity
  • urine ketone body present
2 - 5 years:
  • appetite increased
  • thirst
not specified:
  • diabetes mellitus
  • hepatic necrosis
  • hyponatraemia
  • intestinal ischaemia
  • splenic necrosis
  • arterial thrombosis
  • protein c decreased
  • protein s decreased
  • application site erythema
  • asthenia

Most common drug interactions by gender *:

female:
  • hepatic necrosis
  • hyponatraemia
  • intestinal ischaemia
  • splenic necrosis
  • arterial thrombosis
  • protein c decreased
  • protein s decreased
  • asthenia
  • bowel incontinence
  • compulsive shopping
male:
  • diabetes mellitus
  • drug ineffective
  • tardive dyskinesia
  • application site erythema
  • blood glucose increased
  • diabetes mellitus insulin-dependent
  • diabetic ketoacidosis
  • faecal incontinence
  • nausea
  • sedation

Most common drug interactions by age *:

2-9:
  • blood glucose increased
  • diabetes mellitus insulin-dependent
  • drug ineffective
  • nausea
  • urine ketone body present
10-19:
  • diabetes mellitus
  • tardive dyskinesia
  • application site erythema
  • faecal incontinence
  • sedation
  • urinary incontinence
  • abdominal pain upper
  • akathisia
  • anticonvulsant drug level below therapeutic
  • appetite increased
20-29:
  • hepatic necrosis
  • hyponatraemia
  • intestinal ischaemia
  • splenic necrosis
  • arterial thrombosis
  • protein c decreased
  • protein s decreased
  • gastrooesophageal reflux disease
  • ileus
  • abdominal pain
30-39:
  • anxiety
  • asthenia
  • compulsive shopping
  • convulsion
  • depression
  • fatigue
  • pain
  • pathological gambling
  • sudden death
  • suicidal ideation
40-49:
  • death
  • depression
  • fatigue
  • pathological gambling
  • suicidal ideation
  • asthenia
  • compulsive shopping
  • convulsion
50-59:
  • bowel incontinence
  • incontinence - urinary
  • thought blocking
  • granulocytopenia
  • leukopenia
60+:
  • myocardial infarction
  • sudden death

* Approximation only. Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Do you take Ddavp and Abilify?

Can you answer these questions?

More questions for: Ddavp, Abilify

You may be interested in these reviews

More reviews for: Ddavp, Abilify

On eHealthMe, Ddavp (desmopressin acetate) is often used to treat diabetes insipidus. Abilify (aripiprazole) is often used to treat bipolar disorder. Find out below the conditions the drugs are used for and how effective they are.

What is the drug used for and how effecitve is it:


NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.